Squarepoint
RPRX icon

Squarepoint’s Royalty Pharma RPRX Stock Holding History

Squarepoint’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,500
Closed -$212K – 5424
2024
Q3 		$212K Buy
+7,500
New +$208K ﹤0.01% 3653

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's RPRX Position: Q2 2026 in Review

Squarepoint reduced its Royalty Pharma (RPRX) stake by 76% in Q2 2026, selling an estimated $53.2M and leaving 326,641 shares worth $18.3M. The position accounts for 0.02% of the portfolio, ranked #738.

Squarepoint first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $64.7M in Q1 2026. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Squarepoint held 326,641 shares of Royalty Pharma worth $18.3M as of Q2 2026.
  • Squarepoint sold 1,022,875 Royalty Pharma shares in Q2 2026, an estimated $53.2M.
  • Royalty Pharma made up 0.02% of Squarepoint's portfolio in Q2 2026, its #738 holding.
  • Squarepoint first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Squarepoint's Royalty Pharma position peaked at $64.7M in Q1 2026.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.